Posted by SalArmy4me on September 8, 2001, at 12:22:59
The one study that showed Moclobemide to be weaker than clomipramine in depression used a wimpy dose of moclobemide (400 mg). All other evidence points out that moclobemide is very effective in depression--as effective as the tricyclics themselves without tricyclic side-effects. I take 600 mg per day without side-effects and it really works...
KRAGH-SORENSEN, PER. Moclobemide Versus Clomipramine in Depressed Patients in General Practice. A Randomized, Double-Blind, Parallel, Multicenter Study. J Clin Psychopharmacology. 15(4S) Aug 95:
"No statistically significant differences in the efficacy of clomipramine and moclobemide were found. Because no statistically significant differences were found in outcome between the two diagnostic groups (endogenous and nonendogenous), Table 5 and Table 6 show the combined results for the two diagnostic groups. The results of the global rating with CGAS and CGAE were uniform: there were no significant differences in therapeutic effect between moclobemide and clomipramine..."
ANGST, JULES. Moclobemide and Tricyclic Antidepressants in Severe Depression: Meta-Analysis and Prospective Studies. Journal of Clinical Psychopharmacology. 15(4S) Supplement 2:16S- Aug 95:
"The comparison of imipramine, another standard antidepressant, with moclobemide did not show any significant differences in efficacy. Here, the majority of studies were done relatively late in the development of moclobemide and therefore with moclobemide doses corresponding to the established 3:1 moclobemide:TCA ratio (moclobemide, 453 mg/day; imipramine, 159 mg/day)."
Beaumont G. A randomised, double-blind, multi-centre, parallel-group study comparing the tolerability and efficacy of moclobemide and dothiepin hydrochloride in depressed patients in general practice. Int Clin Psychopharmacol. 1993;7:159-165:
"Both treatments resulted in significant improvement; this was greater in the dothiepin-treated group and the difference was statistically significant, although clinically small."
Casacchia, M. A placebo-controlled study of the antidepressant activity of moclobemide, a new MAO-A inhibitor. Pharmacopsychiatry 7, 122-125:
"Marked improvement was observed by the CGI in 15 cases treated with Moclobemide and mild to moderate in 5 cases who received placebo. The treatment was well tolerated."
poster:SalArmy4me
thread:78268
URL: http://www.dr-bob.org/babble/20010907/msgs/78268.html